Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function Through β-AR Responsiveness in a Rat Model of Type 2 Diabetes

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 16

PMID 39408945

Authors

Betul R Erdogan

Zeynep E Yesilyurt-Dirican

Irem Karaomerlioglu

Ayhanim Elif Muderrisoglu

Kadir Sevim

Martin C Michel

Ebru Arioglu-Inan

Affiliations

Soon will be listed here.

Abstract

Cardiovascular complications are the major cause of diabetes mellitus-related morbidity and mortality. Increased renin-angiotensin-aldosterone system activity and decreased β-adrenergic receptor (β-AR) responsiveness contribute to diabetic cardiac dysfunction. We evaluated the effect of sacubitril/valsartan (neprilysin inhibitor plus angiotensin receptor antagonist combination) and valsartan treatments on the diabetic cardiac function through β-AR responsiveness and on protein expression of diastolic components. Six-week-old male Sprague Dawley rats were divided into control, diabetic, sacubitril/valsartan (68 mg/kg)-, and valsartan-treated (31 mg/kg) diabetic groups. Diabetes was induced by a high-fat diet plus low-dose streptozotocin (30 mg/kg, intraperitoneal). After 10 weeks of diabetes, rats were treated for 4 weeks. Systolic/diastolic function was assessed by in vivo echocardiography and pressure-volume loop analysis. β-AR-mediated responsiveness was assessed by in vitro papillary muscle and Langendorff heart experiments. Protein expression of sarcoplasmic reticulum calcium ATPase2a, phospholamban, and phosphorylated phospholamban was determined by Western blot. Sacubitril/valsartan improved ejection fraction and fractional shortening to a similar extent as valsartan alone. None of the treatments affected in vivo diastolic parameters or the expression of related proteins. β-/β-AR-mediated responsiveness was partially restored in treated animals. β-AR-mediated cardiac relaxation (an indicator of diastolic function) responses were comparable among groups. The beneficial effect of sacubitril/valsartan on systolic function may be attributed to improved β-/β-AR responsiveness.

References

Fu Q, Shi Q, West T, Xiang Y . Cross-Talk Between Insulin Signaling and G Protein-Coupled Receptors. J Cardiovasc Pharmacol. 2017; 70(2):74-86. PMC: 5734060. DOI: 10.1097/FJC.0000000000000481. View

Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T . LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 2016; 18(4):386-93. DOI: 10.1002/ejhf.474. View

Eiringhaus J, Wunsche C, Tirilomis P, Herting J, Bork N, Nikolaev V . Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca leak in human ventricular cardiomyocytes of patients with end-stage heart failure. ESC Heart Fail. 2020; 7(5):2992-3002. PMC: 7586991. DOI: 10.1002/ehf2.12918. View

Feng Y, Wang D, Bi H, Zhang H . The role of natriuretic peptides in diabetes and its complications. Biomed Pharmacother. 2016; 84:1826-1832. DOI: 10.1016/j.biopha.2016.10.089. View

Palomer X, Pizarro-Delgado J, Vazquez-Carrera M . Emerging Actors in Diabetic Cardiomyopathy: Heartbreaker Biomarkers or Therapeutic Targets?. Trends Pharmacol Sci. 2018; 39(5):452-467. DOI: 10.1016/j.tips.2018.02.010. View

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

Martens P, Belien H, Dupont M, Vandervoort P, Mullens W . The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018; 36(4):e12435. DOI: 10.1111/1755-5922.12435. View

Watanuki S, Matsuda N, Sakuraya F, Jesmin S, Hattori Y . Protein kinase C modulation of the regulation of sarcoplasmic reticular function by protein kinase A-mediated phospholamban phosphorylation in diabetic rats. Br J Pharmacol. 2003; 141(2):347-59. PMC: 1574184. DOI: 10.1038/sj.bjp.0705455. View

Werner R, Eissler C, Hayakawa N, Arias-Loza P, Wakabayashi H, Javadi M . Left Ventricular Diastolic Dysfunction in a Rat Model of Diabetic Cardiomyopathy using ECG-gated F-FDG PET. Sci Rep. 2018; 8(1):17631. PMC: 6279734. DOI: 10.1038/s41598-018-35986-0. View

10.

Vergaro G, Del Franco A, Carecci A, Ferrari Chen Y, Aimo A, Forini F . Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction. Int J Cardiol. 2024; 409:132203. DOI: 10.1016/j.ijcard.2024.132203. View

11.

Zhang L, Cannell M, Phillips A, Cooper G, Ward M . Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes. 2008; 57(8):2158-66. PMC: 2494698. DOI: 10.2337/db08-0140. View

12.

Hamdani N, van der Velden J . Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol. 2009; 379(4):403-7. DOI: 10.1007/s00210-009-0392-1. View

13.

Dincer U, Bidasee K, Guner S, Tay A, Ozcelikay A, Altan V . The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes. 2001; 50(2):455-61. DOI: 10.2337/diabetes.50.2.455. View

14.

Norden E, Bendiksen B, Andresen H, Bergo K, Espe E, Hasic A . Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload. ESC Heart Fail. 2021; 8(2):918-927. PMC: 8006657. DOI: 10.1002/ehf2.13177. View

15.

Xia Y, Chen Z, Chen A, Fu M, Dong Z, Hu K . LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. J Mol Cell Cardiol. 2017; 108:138-148. DOI: 10.1016/j.yjmcc.2017.06.003. View

16.

Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D . Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019; 8(13):e012272. PMC: 6662364. DOI: 10.1161/JAHA.119.012272. View

17.

Haley J, Thackeray J, Thorn S, DaSilva J . Cardiac β-Adrenoceptor Expression Is Reduced in Zucker Diabetic Fatty Rats as Type-2 Diabetes Progresses. PLoS One. 2015; 10(5):e0127581. PMC: 4440709. DOI: 10.1371/journal.pone.0127581. View

18.

Liu X, Liu F, Deng C, Zhang M, Yang M, Xiao D . Left ventricular deformation associated with cardiomyocyte Ca(2+) transients delay in early stage of low-dose of STZ and high-fat diet induced type 2 diabetic rats. BMC Cardiovasc Disord. 2016; 16:41. PMC: 4754853. DOI: 10.1186/s12872-016-0220-8. View

19.

Esser N, Zraika S . Neprilysin inhibition: a new therapeutic option for type 2 diabetes?. Diabetologia. 2019; 62(7):1113-1122. PMC: 6579747. DOI: 10.1007/s00125-019-4889-y. View

20.

Yamamoto K, Rakugi H . Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment. Hypertens Res. 2021; 44(10):1239-1250. DOI: 10.1038/s41440-021-00706-1. View